K-RAS gene mutations in patients with non-small cell lung cancer.
- Author:
Yang ZHANG
1
;
Zhenkui PAN
;
Xing ZHANG
;
Fei XU
;
Li ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Non-Small-Cell Lung; genetics; Female; Humans; Lung Neoplasms; genetics; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; genetics; Proto-Oncogene Proteins p21(ras); ras Proteins; genetics
- From: Chinese Journal of Lung Cancer 2010;13(6):602-606
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND AND OBJECTIVERecent studies indicated that Non-small cell lung cancer (NSCLC) patients with mutant K-RAS failed to benefit from adjuvant chemotherapy, and the cancer did not respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). These findings indicated that K-RAS gene status can be a biomarker to predict the sensitivity of EGFR TKIs. The aim of this study is to analyze K-RAS gene mutations with NSCLC patients in Cancer Center of Sun Yet-sen University.
METHODS52 fresh frozen tumor tissues were collected and K-RAS genes were amplified by PCR. Then PCR amplification fragments were sequenced and analyzed.
RESULTSSomatic mutations in the codon 12 of K-RAS gene in tumors were identified from 2 of 52 (3.8%) patients. There were no relationships among K-RAS gene mutations and gender, pathology, smoking, differentiation and stage.
CONCLUSIONThe frequency of K-RAS gene mutations with NSCLC in our center is very low and is similar to that in Asia patients, and is lower than that in Caucasian population.
